# GMED — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-08-13. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 7.4 · Fundamentals 8.3 · Technicals 6.3 · Growth 8.3 · Risk 5.5

## Summary

GMED shows strong fundamentals with robust revenue growth and healthy margins, but technicals indicate near-term volatility ahead of earnings. The current price is trading above the 50-day SMA with support at $84.75 and resistance at $96.00, while analyst consensus targets sit between $87.25 (base) and $103.23 (fair value).

## Price targets (6-month horizon)

- Bear: $87.38
- Base: $95.24
- Bull: $103.23

## News context

Recent news highlights a split narrative: analysts upgraded GMED to Zacks Rank #1 (Strong Buy) due to earnings strength, but fair value was cut from $107.42 to $103.23 reflecting softer growth expectations. The company reaffirmed 2026 revenue guidance and reported Q2 revenue of $789.6M (+6% YoY), with spine and trauma businesses offsetting declines in Nevro sales. However, the market is pricing in significant upside from robotics adoption, making execution risk paramount.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/gmed-ai-stock-forecast-856377b36997aa07966af488c6abb9d1
- AI-generated; model outputs can be wrong. Not financial advice.